---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024154"
form_type: "8-K"
ticker: "ITRMF"
cik: "0001659323"
company_name: "Iterum Therapeutics plc"
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:07:06.942385+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Iterum Q3 net loss $29.1M; starts uUTI trial; cash into 2024

## Summary
- Net loss $29.1M vs income $3.7M YoY; non-GAAP net loss $5.3M.
- Cash, equivalents & short-term investments $64.3M; runway into 2024.
- R&D expense $4.4M (up from $1.8M) due to REASSURE trial startup.
- Enrollment in Phase 3 REASSURE trial for uUTI began Oct 2022; completion expected H1 2024.
- New US patent (No. 11,478,428) for oral sulopenem bilayer tablet extends protection to 2039.

## SEC filing metadata
- accession: 0000950170-22-024154
- form_type: 8-K
- ticker: ITRMF
- cik: 0001659323
- company_name: Iterum Therapeutics plc
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659323/000095017022024154/0000950170-22-024154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659323/000095017022024154/itrm-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024154
- JSON: https://secwatch.observer/filing/0000950170-22-024154.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024154.txt

## Key facts
- Earnings Releases
  Iterum Therapeutics plc reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659323/000095017022024154/0000950170-22-024154-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.